Emerging Pharmacology : Inhibitors of Human Immunodeficiency Virus IntegrationHAZUDA, Daria; IWAMOTO, Marian; WENNING, Larissa et al.Annual review of pharmacology and toxicology (Print). 2009, Vol 49, pp 377-394, issn 0362-1642, 18 p.Article

An extended point-area deconvolution approach for assessing drug input ratesYEH, Kuang C; HOLDER, Daniel J; WINCHELL, Gregory A et al.Pharmaceutical research. 2001, Vol 18, Num 10, pp 1426-1434, issn 0724-8741Article

Raltegravir In Vitro Effect on Bilirubin BindingCLARKE, Diana F; WONG, Ronald J; WENNING, Larissa et al.The Pediatric infectious disease journal. 2013, Vol 32, Num 9, pp 978-980, issn 0891-3668, 3 p.Article

Fully automated liquid-liquid extraction for the determination of a novel insulin sensitizer in human plasma by heated nebulizer and turbo ionspray liquid chromatography-tandem mass spectrometryRIFFEL, Kerry A; GROFF, Michelle A; WENNING, Larissa et al.Journal of chromatography. B. 2005, Vol 819, Num 2, pp 293-300, issn 1570-0232, 8 p.Article

Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected PatientsRIZK, Matthew L; YAMING HANG; LUO, Wen-Lin et al.Antimicrobial agents and chemotherapy. 2012, Vol 56, Num 6, pp 3101-3106, issn 0066-4804, 6 p.Article

Pharmacokinetics, Safety, and 48-Week Efficacy of Oral Raltegravir in HIV-1-Infected Children Aged 2 Through 18 YearsNACHMAN, Sharon; NAN ZHENG; FRENKEL, Lisa M et al.Clinical infectious diseases. 2014, Vol 58, Num 3, pp 413-422, issn 1058-4838, 10 p.Article

Absorption, metabolism, and excretion of [¹⁴C]MK-0524, a prostaglandin D₂ receptor antagonist, in humansKARANAM, Bindhu; MADEIRA, Maria; GARRETT, Graigory et al.Drug metabolism and disposition. 2007, Vol 35, Num 7, pp 1196-1202, issn 0090-9556, 7 p.Article

Ultrasensitive Liquid Chromatography―Tandem Mass Spectrometric Methodologies for Quantification of Five HIV-1 Integrase Inhibitors in Plasma for a Microdose Clinical TrialLI SUN; HANKUN LI; WILLSON, Kenneth et al.Analytical chemistry (Washington). 2012, Vol 84, Num 20, pp 8614-8621, issn 0003-2700, 8 p.Article

Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individualsMARKOWITZ, Martin; MORALES-RAMIREZ, Javier O; WENNING, Larissa et al.Journal of acquired immune deficiency syndromes (1999). 2006, Vol 43, Num 5, pp 509-515, issn 1525-4135, 7 p.Article

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trialSULKOWSKI, Mark; POL, Stanislas; WENNING, Larissa et al.Lancet. Infectious diseases (print). 2013, Vol 13, Num 7, pp 597-605, issn 1473-3099, 9 p.Article

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trialERON, Joseph; ROCKSTROH, Jürgen K; NELSON, Mark et al.Lancet. Infectious diseases (print). 2011, Vol 11, Num 12, pp 907-915, issn 1473-3099, 9 p.Article

Effects of Multiple Doses of Clarithromycin on the Pharmacokinetics of Laropiprant in Healthy SubjectsWANG, Ying-Hong; SCHWARTZ, Jules I; LUO, Wen-Lin et al.Cardiovascular therapeutics (Print). 2011, Vol 29, Num 2, pp 140-145, issn 1755-5914, 6 p.Article

Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy womenANDERSON, Matt S; HANLEY, William D; MOREAU, Allison R et al.British journal of clinical pharmacology. 2011, Vol 71, Num 4, pp 616-620, issn 0306-5251, 5 p.Article

Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzymeKASSAHUN, Kelem; MCINTOSH, Ian; DONGHUI CUI et al.Drug metabolism and disposition. 2007, Vol 35, Num 9, pp 1657-1663, issn 0090-9556, 7 p.Article

Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy SubjectsANDERSON, Matt S; KAKUDA, Thomas N; IWAMOTO, Marian et al.Antimicrobial agents and chemotherapy. 2008, Vol 52, Num 12, pp 4228-4232, issn 0066-4804, 5 p.Article

Effect of Tipranavir-Ritonavir on Pharmacokinetics of RaltegravirHANLEY, William D; WENNING, Larissa A; MOREAU, Allison et al.Antimicrobial agents and chemotherapy. 2009, Vol 53, Num 7, pp 2752-2755, issn 0066-4804, 4 p.Article

Pharmacokinetics of famotidine in infantsWENNING, Larissa A; MURPHY, M. Gail; YEH, Kuang C et al.Clinical pharmacokinetics. 2005, Vol 44, Num 4, pp 395-406, issn 0312-5963, 12 p.Article

Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir PharmacokineticsIWAMOTO, Marian; HANLEY, William D; STONE, Julie A et al.Antimicrobial agents and chemotherapy. 2009, Vol 53, Num 5, pp 1747-1752, issn 0066-4804, 6 p.Article

Lack of a Significant Drug Interaction between Raltegravir and TenofovirWENNING, Larissa A; FRIEDMAN, Evan J; STONE, Julie A et al.Antimicrobial agents and chemotherapy. 2008, Vol 52, Num 9, pp 3253-3258, issn 0066-4804, 6 p.Article

Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of RaltegravirWENNING, Larissa A; HANLEY, William D; STONE, Julie A et al.Antimicrobial agents and chemotherapy. 2009, Vol 53, Num 7, pp 2852-2856, issn 0066-4804, 5 p.Article

Atazanavir Modestly Increases Plasma Levels of Raltegravir in Healthy SubjectsIWAMOTO, Marian; WENNING, Larissa A; STONE, Julie A et al.Clinical infectious diseases. 2008, Vol 47, Num 1, pp 137-140, issn 1058-4838, 4 p.Article

Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection : Results of a 48-week controlled studyMARKOWITZ, Martin; NGUYEN, Bach-Yen; GILDE, Lucinda R et al.Journal of acquired immune deficiency syndromes (1999). 2007, Vol 46, Num 2, pp 125-133, issn 1525-4135, 9 p.Article

Minimal Effects of Ritonavir and Efavirenz on the Pharmacokinetics of RaltegravirIWAMOTO, Marian; WENNING, Larissa A; HAAZEN, Wouter et al.Antimicrobial agents and chemotherapy. 2008, Vol 52, Num 12, pp 4338-4343, issn 0066-4804, 6 p.Article

Effects of Omeprazole on Plasma Levels of RaltegravirIWAMOTO, Arian; WENNING, Larissa A; AZROLAN, Neal et al.Clinical infectious diseases. 2009, Vol 48, Num 4, pp 489-492, issn 1058-4838, 4 p.Article